TPE:1762's EV-to-FCF is ranked worse than 73.86% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs TPE:1762: 43.90
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chunghwa Chemical Synthesis & Biotech Co's PE Ratio (TTM) for today is calculated as:
Chunghwa Chemical Synthesis & Biotech Co's share price for today is NT$38.15.
Chunghwa Chemical Synthesis & Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-4.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Chunghwa Chemical Synthesis & Biotech Co EV-to-FCF Related Terms
Chunghwa Chemical Synthesis & Biotech Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co EV-to-FCF Chart
Chunghwa Chemical Synthesis & Biotech Co Annual Data
TPE:1762 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chunghwa Chemical Synthesis & Biotech Co EV-to-FCF vs Biotechnology Industry
Chunghwa Chemical Synthesis & Biotech Co's current Enterprise Value is NT$3,523.8 Mil.
Chunghwa Chemical Synthesis & Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$80.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a EV-to-FCF of 43.90 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. This is 212% above median its historical median of 14.07. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #243 out of 329 companies in the Biotechnology industry, placing it in the top 73.9%.
Is Chunghwa Chemical Synthesis & Biotech Co's EV-to-FCF too high?
Chunghwa Chemical Synthesis & Biotech Co's current EV-to-FCF of 43.90 is 212% above median its 10-year median of 14.07. The Biotechnology industry median EV-to-FCF is 15.85. Chunghwa Chemical Synthesis & Biotech Co's value of 43.90 is 177% above this industry median. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #243 out of 329 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #243 out of 329 companies for EV-to-FCF. This places Chunghwa Chemical Synthesis & Biotech Co in the lower half of its industry. The industry median EV-to-FCF is 15.85. Chunghwa Chemical Synthesis & Biotech Co's value of 43.90 is 177% above this benchmark. While the company's 10-year median is 14.07 vs. the industry median of 15.85, Chunghwa Chemical Synthesis & Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chunghwa Chemical Synthesis & Biotech Co's current EV-to-FCF of 43.90 is 177% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chunghwa Chemical Synthesis & Biotech Co's current EV-to-FCF is 43.90, which is 212% above median its own 10-year median of 14.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Fairly Valued. The stock's GF Value™ is NT$37.92, compared to a current price of NT$38.15 — trading 0.6% above its estimated fair value. The current EV-to-FCF is 43.90, which is 212% above median its 10-year median of 14.07 and 177% above the Biotechnology industry median of 15.85. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current EV-to-FCF is 43.90 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be overvalued.
The current stock price of NT$38.15 is trading 0.6% above its estimated GF Value™ of NT$37.92.
GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1762:
EV-to-FCF: 43.90 (212% above median its 10-year median of 14.07)
GF Value™: NT$37.92 vs. price of NT$38.15 (0.6% above fair value)
Industry Position: 177% above the Biotechnology median (#243 of 329)
No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chunghwa Chemical Synthesis & Biotech Co Business Description
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
58GF Score
Get the complete analysis for TPE:1762
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1762 has been successfully added to your 
